Sage stock collapsed to a record low. Please watch the video at Investors.com - How To Sell Stocks: Long-Term Trend Lines Wedbush analyst Laura Chico says it's hard to tell whether the drug failed ...

In return Sage gets $1.525 billion upfront – $875 million in cash and a $650 million equity investment – as well as potential milestones of $1.6 billion if both drugs meet their development ...

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study. Topline results from the ...

Lastly, Mizuho Securities has reduced Sage Therapeutics' price target to $6.00, maintaining a Neutral rating following the recent cessation of development for Sage's drug, dalzanemdor, after it ...

BofA withdrew its rating on SAGE in January after the depression drug developer said that Biogen (NASDAQ:BIIB) agreed to buy all the outstanding shares of its common stock that it currently does ...

Researchers at Scripps Research have developed a more stable version of this compound, called diAcCA, and found that it ...

Ten pro-life researchers have challenged an academic journal s retraction of their studies analyzing the risks of abortion, arguing that the publication s actions were politically motivated ...

"I had found strange drugs and a weird note, and my sister was dead," Sage Dreith said. She took jurors back to January 17, 2022, when investigators found her sister, Jade, on the floor two days ...